Fig 4.

Cumulative incidences of death resulting from (A) secondary malignancies and (B) acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Estimates of 10-year cumulative incidence were (A) 3.2% and 7.1% (P = .16) and (B) 0.9% and 4.0% (P = .02) in the R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) and CHOP-RIT (cyclophosphamide, doxorubicin, vincristine, and prednisone followed by consolidation with iodine-133–tositumomab radioimmunotherapy) groups, respectively.